The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice?
de Boer
W A
WA
Sint Anna Ziekenhuis, Dept. of Internal Medicine, Oss, The Netherlands.
Tytgat
G N
GN
D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013752:Tetracycline / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D009942:Organometallic Compounds; D008795:Metronidazole; D000658:Amoxicillin; D013752:Tetracycline; D017291:Clarithromycin; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole; D001729:Bismuth